Post Cardiac SurgeryNCT02569008
Minimal Volume for Fluid Challenge in Post-operative Patients
A study testing Fluid challenge with Compound Sodium Lactate in people with Post Cardiac Surgery, run by St George's, University of London at 1 site in United Kingdom.
Trial summary
This study evaluate the effect of different doses of crystalloids on the changes on cardiac output (CO) and on the proportion of responders and non-responders and aims to determine the minimal volume required to increase the mean systemic filling pressures (Pmsf) in post-cardiac surgical patients. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Post Cardiac Surgery
- What is being tested?
- Fluid challenge with Compound Sodium Lactate
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Jan 2014to Feb 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients admitted to the general or cardiothoracic intensive care unit, requiring fluid therapy guided by the current clinical protocol.
Who cannot join
- Extensive peripheral arterial occlusive disease in upper limbs.
- Postoperative valvular insufficiency
- Aortic valve regurgitation
- Arrhythmia
- Cardiac assist device (Intra-Aortic balloon pump)
- Right ventricular failure
- Patients without capacity to consent for themselves Also, patients requiring aggressive fluid resuscitation due to life-threatening cardiovascular instability and pregnant women will be excluded from the study.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
St George's University Hospitals, NHS Foundation Trust
London, London, SW17 0QT
About this study
Official title: Study of Changes on Mean Systemic Filling Pressure (Pmsf) in Post-surgical Patients After a Fluid Challenge: Looking for the Minimal Dose of Fluids
This study evaluate the effect of different doses of crystalloids on the changes on cardiac output (CO) and on the proportion of responders and non-responders and aims to determine the minimal volume required to increase the mean systemic filling pressures (Pmsf) in post-cardiac surgical patients.
Read the detailed description
OBJECTIVES
- To determine if different doses of fluids in a fluid challenge affect the change in CO and the proportion of responders / non-responders
- To determine the minimal amount of volume required for performing an effective fluid challenge.
- To define the least significant change of the Pmsf measured by Pmsf-arm.
- To define the stop-flow time required to measure Pmsf-arm
- To study the changes generated by a fluid challenge in the microcirculation and correlate those changes with the changes in the Pmsf.
STUDY DESIGN
- TYPE OF STUDY This is an quasi-randomised open-label study. The purpose of this study is non-commercial.
- STUDY OF MINIMAL VOLUME Once the participant is admitted to the ICU, and the monitors are in place, the fluid challenge will be administered. Each fluid challenge will be administered with a syringe (50 ml) in five minutes. In order to observe the effect of the volume on Pmsf-arm, the total sample of patients will be divided in 4 groups: in group one Pmsf-arm will be measured at baseline and after 1 ml/kg of body weight; in group 2 after 2 ml/Kg; in group 3 after 3 ml/kg and finally in group 4 after 4 ml/Kg. The fluid challenge will be completed in everybody after the measurement of Pmsf-arm, in order to respect clinical practice. Pmsa will be observed also. The total duration of the fluid challenge will be 5 minutes. The fluid challenge will be repeated in accordance with the clinical protocol or with the clinician advice. The first 20 patients will receive 4 ml/kg (normal clinical practice) between the base line and the second measurement of Pmsf-arm. The subsequent 20 patients will receive 3ml/kg between the two measurements of Pmsf-arm, and then 1ml/kg will be added to complete the normal fluid challenge. The following 20 patients will receive 2 ml/Kg between the two measurement of Pmsf-arm, and then the remaining 2 ml/kg will be given to complete the normal fluid challenge. And finally, the last 20 patients will receive 1 ml/kg between the two measurements of Pmsf-arm, and 3 ml/kg will be added to complete clinical practice.
- STUDY OF MICROCIRCULATION In 25 patients, functional capillary density (FCD) microvascular flow index (MFI), proportion of perfused vessels (PPV) and microvascular heterogeneity index (MHI) will be measured with a side-stream dark-field (SDF) camera at five time points: (1)Baseline, (2) At the end of the fluid challenge (4 ml / kg in 5 minutes), (3) 5 minutes after the end of the fluid challenge, (4) 10 minutes after the end of the fluid challenge, (5) 15 minutes after the end of the fluid challenge. The ventilation settings, sedation and vasoactive support will be kept constant during the study period, unless other clinical instruction, in which case the data will be excluded from the analysis.
- HAEMODYNAMIC MEASUREMENTS
4.1 CLINICAL MONITORING These measurements are using normally in clinical practice and will be used during the study but do not constitute any change in clinical practice.
- Mean arterial pressure (MAP) will be measured with a radial artery catheter (p.e. 115.090 Vygon, Ecouen, France).
- Central venous pressure (CVP) will be measured with a venous central catheter (p.e. CV-15854, Arrow International, Reading, USA) inserted in the internal jugular vein or the subclavian vein. This line will be ideally inserted in the anaesthetic room after induction of general anaesthesia. Once the study finishes, this line will be removed unless the clinical team taking care of the patient decided to use it.
- Both catheters will be connected to a pressure transducer (T001650A, Edwards Lifesciences LLC, Irvine, USA) and to a multi-parameter monitor (InfinityTM Delta, Dragger Medical Systems, USA). Zero levels of blood pressures were referenced to the intersection of the anterior axillary line and the fifth intercostal space.
- Cardiac output will be monitored using LiDCO TM plus (LiDCO Ltd, Cambridge, UK)
4.2 DETERMINATION OF PMSF-ARM Pmsf can be estimated measuring the venous pressure (Pv) and the arterial pressure (Pa) in on limb after rapid vascular occlusion. This estimation assumes Pa and Pv equilibrium following a rapid vascular occlusion as described by Maas et al[2]. In order to determine stop-flow time (or time of arterial / venous balance), we will perform a pilot study in 10 patients. We will measure the radial arterial pressure and venous pressure in the same hand and we will then stop the blood-flow during 30 -60 seconds using an automatic pneumatic tourniquet (APT pneumatic tourniquet, Anetic Aid, Ltd. Guiseley, UK) to pressures 50 mmHg above systolic pressure. Measures will be taken three times in order to assess repeatability. The time required to equilibrate arterial and venous pressure will be the stop-flow time, and will be the time that we need to wait with the tourniquet inflated. In Maas study was between 25 - 30 seconds.
4.3 MICROCIRCULATION MEASUREMENTS
In order to study microcirculatory changes, sublingual microcirculatory videos will be obtained using a side-stream dark field-imaging device (SDF; Microscan, MicroVissionMedical, Amsterdam, the Nederlands) derived from the orthogonal polarized spectral imaging technology. Images acquisition and analysis will be performed according international recommendations [3] with dedicated software analysis (Automated Vascular Analysis (AVA) v. 1.0; Academic Medical Center, University of Amsterdam, Amsterdam, the Nederlands). These recommendations are summarised below:
- Image acquisition will include five sublingual good quality sequences of 20 seconds each at every observation time-point.
- Scoring will include measurement of perfused capillary density and evaluation of heterogeneity. We will measure:
- Functional capillary density (FCD): this can be calculated counting the number of intersection of capillaries with arbitrary grid lines and measurement of total capillary length relative to image area.
- Microcirculatory flow index (MFI): this is based on determination of the predominant type of flow in four quadrants. Flow is characterised as absent (0), intermittent (1), sluggish (2) or normal (3). The values of the four quadrants is averaged.
- Proportion of perfused vessels (PPV %): calculated as the total number of vessels minus the number of vessels with intermittent flow or no flow divided by the total number of vessels.
- Flow heterogeneity index (FHI): the difference between the highest MFI minus the lowest site MFI divided by the mean flow velocity of all sublingual sites at a single time point.
SETTING General and cardiothoracic intensive care unit, St George's Healthcare Trust.
- Conditions
- Post Cardiac Surgery
- Being tested
- Fluid challenge with Compound Sodium Lactate
- Keywords
- Fluid Challenge, Mean systemic filling pressure, Fluid therapy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fluid challenge with Compound Sodium LactateDrug
Also called Hartmann's Solution
Infusion of the mentioned dose of Compound sodium Lactate over 5 minutes intravenously.
| Study group | Role | What they receive |
|---|---|---|
| 1 ml / Kg | Experimental | Patients receive a Fluid challenge with Compound Sodium Lactate 1 ml/Kg IV over 5 minutes Receives: Drug: Fluid challenge with Compound Sodium Lactate |
| 2 ml/Kg | Experimental | Patients receive a Fluid challenge with Compound Sodium Lactate 2 ml/Kg IV over 5 minutes Receives: Drug: Fluid challenge with Compound Sodium Lactate |
| 3 ml/Kg | Experimental | Patients receive a Fluid challenge with Compound Sodium Lactate 3 ml/Kg IV over 5 minutes Receives: Drug: Fluid challenge with Compound Sodium Lactate |
| 4 ml/Kg | Experimental | Patients receive a Fluid challenge with Compound Sodium Lactate 4 ml/Kg IV over 5 minutes Receives: Drug: Fluid challenge with Compound Sodium Lactate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of Responders by dose group
Proportion of responders to a fluid challenge by dose of crystalloids according to CO response (greater than 10% change in CO is a positive response)
Measured: 15 minutes
Secondary outcomes (2)
Change in Pmsf by dose of fluids
change in Pmsf achieved by each group adjusted by baseline values
Measured: 15 Minutes
Minimal dose of fluids
Estimated minimal dose of fluids required to achieve a significant change in Pmsf
Measured: 15 Minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Oct 2015 (estimated)
- Study startJan 2014
- Primary completionFeb 2015
- Study completionFeb 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Post Cardiac SurgeryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- St George's, University of London
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Hollmann D Aya, M.D., Principal investigator, St George's University Hospitals NHS Foundation TrustMaurizio Cecconi, MD(Res), Study director, St George's University Hospitals NHS Foundation Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02569008
- Sponsor's protocol ID
- 13.0116
- Status last verified
- Oct 2015
- First submitted
- 2 Oct 2015
- Last updated
- 9 Oct 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of Changes on Mean Systemic Filling Pressure (Pmsf) in Post-surgical Patients After a Fluid Challenge: Looking for the Minimal Dose of Fluids
- ClinicalTrials.gov ID
- NCT02569008
- Acronym / sponsor ID
- 13.0116
- Conditions
- Post Cardiac Surgery
- Keywords
- Fluid Challenge, Mean systemic filling pressure, Fluid therapy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- St George's, University of LondonUniversity, hospital or other
- Study start
- Jan 2014
- Primary completion
- Feb 2015 (actual)
- Study completion
- Feb 2015 (actual)
- First posted
- 6 Oct 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluate the effect of different doses of crystalloids on the changes on cardiac output (CO) and on the proportion of responders and non-responders and aims to determine the minimal volume required to increase the mean systemic filling pressures (Pmsf) in post-cardiac surgical patients.
Detailed description
OBJECTIVES
- To determine if different doses of fluids in a fluid challenge affect the change in CO and the proportion of responders / non-responders
- To determine the minimal amount of volume required for performing an effective fluid challenge.
- To define the least significant change of the Pmsf measured by Pmsf-arm.
- To define the stop-flow time required to measure Pmsf-arm
- To study the changes generated by a fluid challenge in the microcirculation and correlate those changes with the changes in the Pmsf.
STUDY DESIGN
- TYPE OF STUDY This is an quasi-randomised open-label study. The purpose of this study is non-commercial.
- STUDY OF MINIMAL VOLUME Once the participant is admitted to the ICU, and the monitors are in place, the fluid challenge will be administered. Each fluid challenge will be administered with a syringe (50 ml) in five minutes. In order to observe the effect of the volume on Pmsf-arm, the total sample of patients will be divided in 4 groups: in group one Pmsf-arm will be measured at baseline and after 1 ml/kg of body weight; in group 2 after 2 ml/Kg; in group 3 after 3 ml/kg and finally in group 4 after 4 ml/Kg. The fluid challenge will be completed in everybody after the measurement of Pmsf-arm, in order to respect clinical practice. Pmsa will be observed also. The total duration of the fluid challenge will be 5 minutes. The fluid challenge will be repeated in accordance with the clinical protocol or with the clinician advice. The first 20 patients will receive 4 ml/kg (normal clinical practice) between the base line and the second measurement of Pmsf-arm. The subsequent 20 patients will receive 3ml/kg between the two measurements of Pmsf-arm, and then 1ml/kg will be added to complete the normal fluid challenge. The following 20 patients will receive 2 ml/Kg between the two measurement of Pmsf-arm, and then the remaining 2 ml/kg will be given to complete the normal fluid challenge. And finally, the last 20 patients will receive 1 ml/kg between the two measurements of Pmsf-arm, and 3 ml/kg will be added to complete clinical practice.
- STUDY OF MICROCIRCULATION In 25 patients, functional capillary density (FCD) microvascular flow index (MFI), proportion of perfused vessels (PPV) and microvascular heterogeneity index (MHI) will be measured with a side-stream dark-field (SDF) camera at five time points: (1)Baseline, (2) At the end of the fluid challenge (4 ml / kg in 5 minutes), (3) 5 minutes after the end of the fluid challenge, (4) 10 minutes after the end of the fluid challenge, (5) 15 minutes after the end of the fluid challenge. The ventilation settings, sedation and vasoactive support will be kept constant during the study period, unless other clinical instruction, in which case the data will be excluded from the analysis.
- HAEMODYNAMIC MEASUREMENTS
4.1 CLINICAL MONITORING These measurements are using normally in clinical practice and will be used during the study but do not constitute any change in clinical practice.
- Mean arterial pressure (MAP) will be measured with a radial artery catheter (p.e. 115.090 Vygon, Ecouen, France).
- Central venous pressure (CVP) will be measured with a venous central catheter (p.e. CV-15854, Arrow International, Reading, USA) inserted in the internal jugular vein or the subclavian vein. This line will be ideally inserted in the anaesthetic room after induction of general anaesthesia. Once the study finishes, this line will be removed unless the clinical team taking care of the patient decided to use it.
- Both catheters will be connected to a pressure transducer (T001650A, Edwards Lifesciences LLC, Irvine, USA) and to a multi-parameter monitor (InfinityTM Delta, Dragger Medical Systems, USA). Zero levels of blood pressures were referenced to the intersection of the anterior axillary line and the fifth intercostal space.
- Cardiac output will be monitored using LiDCO TM plus (LiDCO Ltd, Cambridge, UK)
4.2 DETERMINATION OF PMSF-ARM Pmsf can be estimated measuring the venous pressure (Pv) and the arterial pressure (Pa) in on limb after rapid vascular occlusion. This estimation assumes Pa and Pv equilibrium following a rapid vascular occlusion as described by Maas et al[2]. In order to determine stop-flow time (or time of arterial / venous balance), we will perform a pilot study in 10 patients. We will measure the radial arterial pressure and venous pressure in the same hand and we will then stop the blood-flow during 30 -60 seconds using an automatic pneumatic tourniquet (APT pneumatic tourniquet, Anetic Aid, Ltd. Guiseley, UK) to pressures 50 mmHg above systolic pressure. Measures will be taken three times in order to assess repeatability. The time required to equilibrate arterial and venous pressure will be the stop-flow time, and will be the time that we need to wait with the tourniquet inflated. In Maas study was between 25 - 30 seconds.
4.3 MICROCIRCULATION MEASUREMENTS
In order to study microcirculatory changes, sublingual microcirculatory videos will be obtained using a side-stream dark field-imaging device (SDF; Microscan, MicroVissionMedical, Amsterdam, the Nederlands) derived from the orthogonal polarized spectral imaging technology. Images acquisition and analysis will be performed according international recommendations [3] with dedicated software analysis (Automated Vascular Analysis (AVA) v. 1.0; Academic Medical Center, University of Amsterdam, Amsterdam, the Nederlands). These recommendations are summarised below:
- Image acquisition will include five sublingual good quality sequences of 20 seconds each at every observation time-point.
- Scoring will include measurement of perfused capillary density and evaluation of heterogeneity. We will measure:
- Functional capillary density (FCD): this can be calculated counting the number of intersection of capillaries with arbitrary grid lines and measurement of total capillary length relative to image area.
- Microcirculatory flow index (MFI): this is based on determination of the predominant type of flow in four quadrants. Flow is characterised as absent (0), intermittent (1), sluggish (2) or normal (3). The values of the four quadrants is averaged.
- Proportion of perfused vessels (PPV %): calculated as the total number of vessels minus the number of vessels with intermittent flow or no flow divided by the total number of vessels.
- Flow heterogeneity index (FHI): the difference between the highest MFI minus the lowest site MFI divided by the mean flow velocity of all sublingual sites at a single time point.
SETTING General and cardiothoracic intensive care unit, St George's Healthcare Trust.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| 1 ml / Kg | Experimental | Drug: Fluid challenge with Compound Sodium LactatePatients receive a Fluid challenge with Compound Sodium Lactate 1 ml/Kg IV over 5 minutes |
| 2 ml/Kg | Experimental | Drug: Fluid challenge with Compound Sodium LactatePatients receive a Fluid challenge with Compound Sodium Lactate 2 ml/Kg IV over 5 minutes |
| 3 ml/Kg | Experimental | Drug: Fluid challenge with Compound Sodium LactatePatients receive a Fluid challenge with Compound Sodium Lactate 3 ml/Kg IV over 5 minutes |
| 4 ml/Kg | Experimental | Drug: Fluid challenge with Compound Sodium LactatePatients receive a Fluid challenge with Compound Sodium Lactate 4 ml/Kg IV over 5 minutes |
Who may qualify
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Patients admitted to the general or cardiothoracic intensive care unit, requiring fluid therapy guided by the current clinical protocol.
Key exclusion criteria (7 listed)
- Extensive peripheral arterial occlusive disease in upper limbs.
- Postoperative valvular insufficiency
- Aortic valve regurgitation
- Arrhythmia
- Cardiac assist device (Intra-Aortic balloon pump)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fluid challenge with Compound Sodium LactateAlso: Hartmann's SolutionInfusion of the mentioned dose of Compound sodium Lactate over 5 minutes intravenously. | Drug | 1 ml / Kg, 2 ml/Kg, 3 ml/Kg, 4 ml/Kg |
Primary outcome
Proportion of Responders by dose group
Time frame: 15 minutes
Proportion of responders to a fluid challenge by dose of crystalloids according to CO response (greater than 10% change in CO is a positive response)
2 secondary outcomes
Change in Pmsf by dose of fluids
Time frame: 15 Minutes
Minimal dose of fluids
Time frame: 15 Minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2015.
Related trials for Post Cardiac Surgery
Active, not recruitingObservational study
Associations of Postoperative Hemoglobin With AKI-AKD Trajectories
Patients Undergoing Valvular Heart Surgery
Not yet recruiting
Starry-Sky Projection and Maternal Voice for Sleep After Pediatric Cardiac Surgery
Congenital Heart Disease (CHD), Postoperative Sleep
RecruitingPhase 1/2
Butyric Acid Supplementation for Gut Improvement After Cardiac Surgery in Kids
Congenital Heart Disease (CHD)
Not yet recruiting
Randomized Evaluation of Operating Room Extubation After Cardiac Surgery
Cardiac Surgery
Not yet recruitingObservational study
Biomarkers of Postoperative Complications After Cardiac Surgery
Postoperative Complications
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hollmann D Aya, M.D. principal investigator
St George's University Hospitals NHS Foundation Trust
Maurizio Cecconi, MD(Res) study director
St George's University Hospitals NHS Foundation Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Fluid challenge with Compound Sodium Lactate in people with Post Cardiac Surgery, run by St George's, University of London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Oct 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of Responders by dose group (time frame: 15 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2015.